Pediatric gastroenterology

KATE FARMS PEDIATRIC BLENDED MEALS NOW AVAILABLE

Retrieved on: 
Wednesday, January 24, 2024
Fruit, Allergen, Vitamin, Drinking, Insurance, Nutrition, Broward Health, Today, Caregiver, Vegetable, HCPCS, Parent, Mineral, Dietitian, Pediatric gastroenterology, Nursing

"Kate Farms listened," said Dr. Debora Duro, Program Director of Pediatric Gastroenterology, Hepatology and Nutrition at Broward Health. "We--clinicians, parents and caregivers—have been asking for whole food variety, convenience and smart packaging, and Kate Farms delivered. A new package that easily connects to common tube feeding devices is truly innovative, and the kid-friendly design will make the little ones smile too."

Key Points: 
  • SANTA BARBARA, Calif., Jan. 23, 2024 /PRNewswire/ -- Kate Farms ® the #1 prescribed plant-based brand, launched its first Pediatric Blended Meals innovation, bringing to market the first plant-based, organic, whole-food blended meals designed for ease and convenience.
  • Kate Farms Pediatric Blended Meals are designed for children ages one to 13 to help support their healthy growth and development and can be used for both tube and oral feeding.
  • Kate Farms Pediatric Blended Meals have no common allergens, and do not contain any artificial sweeteners, flavors, colors, or preservatives.
  • Kate Farms Pediatric Blended Meals are eligible for insurance coverage under HCPCS code B4149.

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Retrieved on: 
Tuesday, January 9, 2024
Research, Teens, Children, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Phase, Food, Constipation, Division, University of Miami, G.I., Pediatric gastroenterology, Medication, Ageing, Linaclotide, Defecation, SBM, University, Nutrition, Knowledge, Ironwood Pharmaceuticals, Functional constipation, Patient, The Lancet, Food and Drug Administration

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.
  • Functional constipation in children is defined as a condition with hard, infrequent bowel movements that are often difficult or painful to pass1.
  • Linaclotide (marketed as LINZESS®) 72mcg is available in the U.S. for the treatment of functional constipation for pediatric patients aged 6-17 years old.
  • “The publication of these results in The Lancet Gastroenterology & Hepatology adds to the body of knowledge about linaclotide and helps close the unmet needs gap in pediatric patients ages 6- 17 with FC.”

KATE FARMS ANNOUNCES LAUNCH OF FIRST-EVER WHOLE FOOD BLENDED MEALS IN RESEALABLE POUCHES THAT CONNECT TO COMMON TUBE FEEDING DEVICES

Retrieved on: 
Wednesday, November 1, 2023
Meal, Drinking, Fruit, HCPCS, Medicare, Pediatric gastroenterology, Parent, Vitamin, Form, Broward Health, USDA, GMO, Sugar, Friends, Caregiver, Mineral, Nutrition, Health, Clinical nutrition, Patient, Peptide, Centers for Medicare & Medicaid Services, Vegetable, CMS, Vitamin D, Dietary supplement

"Today marks a significant milestone for Kate Farms as we unveil our latest innovation--Pediatric Blended Meals," said Chief Commercial Officer Catherine Hayden. "This product combines innovative advancements in product design, packaging, and delivery with our unwavering commitment to quality, plant-based ingredients, a value we've upheld since day one."Bottom of Form

Key Points: 
  • Kate Farms Pediatric Blended Meals will introduce the first whole food formulas inspired by meals at home with resealable packaging that directly connects to common tube feeding devices, providing a convenient way to nourish people using feeding tubes.
  • "We--clinicians, parents and caregivers—have been asking for whole food variety, convenience and smart packaging, and Kate Farms delivered.
  • "Today marks a significant milestone for Kate Farms as we unveil our latest innovation--Pediatric Blended Meals," said Chief Commercial Officer Catherine Hayden.
  • "Bottom of Form
    Kate Farms Pediatric Blended Meals are compatible with common ENFit™ tube feeding devices and flow easily through feeding tubes with minimal manipulation like thinning or dilution and are versatile for tube feeding and drinking.

ByHeart Announces New Data Indicating that its First-of-its-Kind, U.S.-Made Infant Formula Improves Sleep Benefits in Infants, According to Clinical Trial Results

Retrieved on: 
Wednesday, May 3, 2023
Nutrition, Birth weight, Life, Digestion, Tryptophan, Parent, Sleep, Clinical trial, Pediatric gastroenterology, Evaporated milk, Coronavirus Scientific Advisory Board, Translation, Breast milk, Protein, Journal, MD, Journal of Pediatric Gastroenterology and Nutrition, Lactoferrin, Blood, Immune system, Infant, Birth control, Dietary supplement

NEW YORK, May 3, 2023 /PRNewswire/ -- Today, ByHeart, a next-generation baby nutrition company, announced new data from its clinical trial demonstrating that its infant formula improves sleep benefits in infants. The data collected in the clinical trial established that four-month-old infants who consumed ByHeart's infant formula, at this important time during sleep development, woke up less to feed overnight and slept longer between feeds, compared to infants who consumed another infant formula. These findings build on previously announced ease of digestion and tolerability data published in the Journal of Pediatric Gastroenterology and Nutrition. ByHeart's patented protein blend includes lactoferrin and alpha-lactalbumin, the two most abundant proteins in breast milk; the company is the first to include alpha-lactalbumin at breast milk levels in infant formula in the American market. Babies fed ByHeart had significantly fewer spit-ups and softer stools than babies fed another infant formula, and more closely resembled breastfed infants.

Key Points: 
  • The data collected in the clinical trial established that four-month-old infants who consumed ByHeart's infant formula, at this important time during sleep development, woke up less to feed overnight and slept longer between feeds, compared to infants who consumed another infant formula.
  • These findings build on previously announced ease of digestion and tolerability data published in the Journal of Pediatric Gastroenterology and Nutrition.
  • Babies fed ByHeart had significantly fewer spit-ups and softer stools than babies fed another infant formula, and more closely resembled breastfed infants.
  • For more detailed information, additional data, and insights from ByHeart's clinical trial study, visit https://byheart.com .

AdvoCare® Hosts “You’ve Got This” Virtual Event on February 15th Offering Health and Wellness Education

Retrieved on: 
Monday, February 13, 2023
Sports, Physical Therapy, Other Health, Health, General Health, Biometrics, Football, Entertainment, Celebrity, Vitamins, Supplements, Fitness & Nutrition, CST, Employment Medical Advisory Service, Virtual event, Pennington Biomedical Research Center, Hospital, Tight end, Science, Professor, Pediatric gastroenterology, Associate, Cleveland Clinic, Multimedia, AdvoCare, Medical device, Visa

AdvoCare International, LLC , a health and wellness company, hosts its annual “You’ve Got This” virtual event with a focus on health and wellness in 2023.

Key Points: 
  • AdvoCare International, LLC , a health and wellness company, hosts its annual “You’ve Got This” virtual event with a focus on health and wellness in 2023.
  • This live-streamed event will take place on February 15th from 6:00 pm to 7:30pm (CST) and is offered to registrants at no cost.
  • View the full release here: https://www.businesswire.com/news/home/20230210005320/en/
    Join Jason Witten and Dr. Elizabeth Lombardo for AdvoCare's You've Got This Virtual Event on February 15th from 6pm - 7:30pm.
  • You’ve Got This event registration is free and open to the public.

University Hospitals Rainbow Babies & Children’s Hospital First in Midwest to Use EvoEndo® System for Pediatric Endoscopy

Retrieved on: 
Tuesday, January 24, 2023
Hospitals, Health, Surgery, Oncology, Stomach, Physician, Diagnosis, Division, Patient, Hospital, Esophagus, Anesthesia, University Hospitals Cleveland Medical Center, University, Endoscopy, Child, EGD, Parent, Pediatric gastroenterology, TNE, Observation, Doctor of Philosophy, Nutrition, MD, Nursing

University Hospitals (UH) Rainbow Babies & Children’s Hospital, a full-service children’s hospital and pediatric academic medical center in Northeast Ohio, is the first care center in the Midwest to use the EvoEndo® Single-Use System to perform an unsedated transnasal endoscopy (TNE).

Key Points: 
  • University Hospitals (UH) Rainbow Babies & Children’s Hospital, a full-service children’s hospital and pediatric academic medical center in Northeast Ohio, is the first care center in the Midwest to use the EvoEndo® Single-Use System to perform an unsedated transnasal endoscopy (TNE).
  • The EvoEndo® System may provide an option for patients five and older to undergo a transnasal esophagogastroduodenoscopy (EGD) exam without anesthesia or sedation.
  • The EvoEndo® Controller is intended for use with an EvoEndo® Endoscope for endoscopic diagnosis, treatment, and video observation.
  • It is a lot easier.”
    “We are excited to partner with University Hospitals Rainbow Babies & Children’s Hospital and its commitment to providing comprehensive, nationally ranked care, and believe that advancements like our EvoEndo® System will enhance clinicians’ ability to serve pediatric patients and their families,” said Heather Underwood, PhD, Chief Executive Officer at EvoEndo.

EvoEndo Announces Ambulatory Payment Classification (APC) Reassignments for Flexible Transnasal Esophagogastroduodenoscopy (EGD)

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Medical Devices, Gastroesophageal reflux disease, Pediatric gastroenterology, Nutrition, CMS, Degenerative disease, Centers for Medicare & Medicaid Services, Italian ship Leonardo (A 5301), VR, Learning, Patient, Biopsy, OPPS, APC, Endoscopy, Eosinophilic esophagitis, EOE, FDA, Malabsorption, EGD, CPT, Virtual reality, Center for Medicare and Medicaid Innovation, Italian ship Ammiraglio Magnaghi (A 5303), Abdominal pain, Columbia University Irving Medical Center, Dysphagia, Physician, TNE, Medicare

We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.

Key Points: 
  • We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.
  • Unsedated transnasal endoscopy with the EvoEndo Single-Use Endoscopy System is designed to reduce preparation and recovery time for upper endoscopy procedures and to eliminate potential risks associated with sedation.
  • The EvoEndo System includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy, and a small portable video controller.
  • The EvoEndo Comfort Kit includes virtual reality (VR) goggles for patient distraction during the unsedated transnasal endoscopy procedure.

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Retrieved on: 
Tuesday, November 15, 2022
Transfer, Perception, Doctor of Philosophy, Intellectual property, Tuba City Regional Health Care Corporation, SEC, Ramot at Tel Aviv University, 3D, Technology, Allergan, MD, Patient, Colitis, Forward-looking statement, Harvard University, Annual report, City, Wyss Institute, Risk, Genetic engineering, Industry, 3D bioprinting, Company, Newsweek, 3D Systems, Ulcerative colitis, Terminology, Tissue, Sheba Medical Center, Research, Marketing, Pediatric gastroenterology, COVID-19, CEO, NASDAQ, Form 20-F, Inflammatory bowel disease, Wyss Institute for Biologically Inspired Engineering, Hospital, Drug discovery, Inflammatory Bowel Diseases, Clinical trial, AbbVie, Bio-ink, Drug development, Disease, Tel HaShomer, Public expenditure, Medical imaging, Pharmaceutical industry, Medical device, Tel Aviv University

Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

Key Points: 
  • Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
  • Kit Parker at the Wyss Institute at Harvard University, Dr. Yael Haberman from the Pediatric Gastroenterology unit of Sheba Medical Center, and CollPlant's team of scientists and engineers.
  • "We are excited to embark on this important collaboration with Tel Aviv University and Sheba Medical Center for what will represent CollPlant's strategic expansion into personalized medicine.
  • About Ramot and Tel Aviv University:
    Ramot is the technology transfer company ofTel Aviv University, one ofIsrael'sforemost research and teaching universities.

Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn's Disease Patients

Retrieved on: 
Wednesday, September 14, 2022
Adult, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Abscess, Trial of the century, National Accreditation Board for Hospitals & Healthcare Providers, Department, Risk, Weight loss, U.S.A, Icahn School of Medicine at Mount Sinai, Takeda Pharmaceutical Company, Pediatrics, Inflammatory bowel disease, Diarrhea, Stenosis, Division, LinkedIn, Pediatric emergency medicine, Partnership, Risk assessment, Head, Patient, Program, Crohn's disease, Physician, Laboratory, CD, Department of Defence, United States Department of Veterans Affairs, CAP, Solution, Bowel obstruction, Prometheus, Insurance, SAN, Abdominal pain, IBD, Health care, Coast guard, Multimedia, Pediatric gastroenterology, Disease, United States Public Health Service, Pharmaceutical industry, Medicine, Health insurance, Medicare, Medicaid, Takeda, Medicine

SAN DIEGO, Sept. 14, 2022 /PRNewswire/ -- Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients.

Key Points: 
  • SAN DIEGO, Sept. 14, 2022 /PRNewswire/ -- Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients.
  • The CDPATH test is a result of a collaboration among Prometheus, MiTest Health LLC ("MiTest") and Takeda Pharmaceutical Company Limited ("Takeda").
  • "With CDPATH, we want to identify patients before they have severe disease and inform discussions with patients about the management of disease."
  • Mike Walther, President of Prometheus Laboratories commented, "We are pleased to partner with Takeda to make CDPATH available to healthcare providers and their patients.

AdvoCare® Hosts “You’ve Got This” Virtual Event on September 13 - to Motivate and Spread Positivity in the Busy Fall and Holiday Seasons

Retrieved on: 
Tuesday, September 13, 2022
Technology, Health, General Health, Women, Food, Beverage, Men, Retail, Family, Fitness & Nutrition, Consumer, Parenting, Maker, Christmas and holiday season, Health, Department, Friedman School of Nutrition Science and Policy, Twitter, LLC, Autumn, Blog, Hospital, Connect, News, Nutrition, Catalog, AdvoCare, Season, CST, Cleveland Clinic, Oral rehydration therapy, Instagram, Associate, Motivation, Multimedia, Pediatric gastroenterology, Online shopping, Policy, Facebook

AdvoCare International, LLC , a health and wellness company, hosts Youve Got This virtual event to motivate and to help everyone make the most of this season, mentally and physically.

Key Points: 
  • AdvoCare International, LLC , a health and wellness company, hosts Youve Got This virtual event to motivate and to help everyone make the most of this season, mentally and physically.
  • The free, live-streamed event will take place on September 13th and from 6:00 pm to 7:30 pm (CST).
  • The 'Youve Got This' virtual event is an opportunity for our AdvoCare community to empower each other to become better versions of themselves.
  • Visit the Connect AdvoCare blog for inspirational content featuring fitness and wellness tips, motivation, testimonials, recipes and more.